ASCO GU 2019 Presentations
Dr. Andrew J. Armstrong, Duke University, NC, USA
ASCO GU 2019 - Dr. Andrew J. Armstrong, Duke University, NC, USA
Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
Dr. Toni Choueiri, Dana-Farber Cancer Institute, USA
ASCO GU 2019 - Dr. Toni Choueiri, Dana-Farber Cancer Institute, USA
Highlights in RCC from ASCO GU 2019.
Dr. Sumanta K. Pal, City of Hope, USA
ASCO GU 2019 - Dr. Sumanta K. Pal, City of Hope, USA
Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC).
Dr. Brian Rini, Cleveland Clinic, USA
ASCO GU 2019 - Dr. Brian Rini, Cleveland Clinic, USA
TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Dr. Paulo Lajes, Dr. Fernando Maluf and Dr. Andrey Soares, Brazil
ASCO GU 2019 - Dr. Paulo Lajes, Dr. Fernando Maluf and Dr. Andrey Soares, Brazil
Take Home Messages from ASCO GU 2019 (Portuguese)
Dr. Manuel Maia, Centro de Oncologia, PR, Brazil
ASCO GU 2019 - Dr. Manuel Maia, Centro de Oncologia, PR, Brazil
Updates in Prostate Cancer from ASCO GU2019.
Dr. Steve Yip, BC Cancer Agency, Canada
ASCO GU 2019 - Dr. Steve Yip, BC Cancer Agency, Canada
Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
Dr. Arjun V Balar, NYU Langone's Pearlmutter Cancer Center, USA
ASCO GU 2019 - Dr. Arjun V Balar, NYU Langone's Pearlmutter Cancer Center, USA
Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
Dra. Karine Trindade and Dr. Fernando Nunes, Brazil
ASCO GU 2019 - Dra. Karine Trindade and Dr. Fernando Nunes, Brazil
Highlights in First Line RCC (Portuguese).
Dr. Orazio Caffo, Santa Chiara Hospital, Italy
ASCO GU 2019 - Dr. Orazio Caffo, Santa Chiara Hospital, Italy
A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
Dra Ana Paula Cardoso, Albert Einstein Hospital, Brazil
ASCO GU 2019 - Dra Ana Paula Cardoso, Albert Einstein Hospital, Brazil
Updates in Urothelial tumors from ASCO GU 2019 (Portuguese).
Dr. Fabio Shutz, BP Hospital, Brazil
ASCO GU 2019 - Dr. Fabio Shutz, BP Hospital, Brazil
Take Home Messages in RCC from ASCO GU 2019 (Portuguese).
Highlights in Bladder Cancer
ASCO GU 2019 - Dr. Guru Sonpavde, Dana-Farber Cancer Institute, USA
ASCO GU 2019 - Dr. Sumit K Subudhi, MD Anderson, USA
ASCO GU 2019 - Dr. Sumit K Subudhi, MD Anderson, USA